ASX Release **15 January 2025**

Presentation at Biotech Showcase 2025

Melbourne, Australia – Tryptamine Therapeutics Limited ('**Tryp**' or the '**Company**') (**ASX: TYP**), a clinical-stage biopharmaceutical company, is pleased to provide the following presentation which will be given at renowned investor conference, the Biotech Showcase 2025, in San Francisco on 15 January 2025.

Biotech Showcase is a dedicated investor conference designed to provide private and micro-mid-cap biotechnology companies with the opportunity to present and connect with investors and industry executives. Tryp was selected as one of 400 companies from across the globe to present its recent findings and progress. Presenting at the event will provide the Company with direct access to investor groups that collectively manage over US$400bn in capital, along with key strategic partners in the life sciences sector.

This announcement has been authorised for release by the Board of Tryptamine Therapeutics Limited.

-ENDS-

About Tryptamine Therapeutics Limited

Tryp Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp's lead asset, TRP-8803, is a proprietary, scalable and innovative formulation of IV-infused psilocin (the active metabolite of psilocybin) with neuroplastic benefits. It has the potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the neuroplastic state, controlling the depth and duration of the neuroplastic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The Company has completed a Phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida, which demonstrated an average reduction in binge eating episodes of greater than 80%.

The Company also has also just completed a Phase 2a successful clinical trial for the treatment of fibromyalgia in collaboration with the University of Michigan and has initiated a Phase 2a clinical trial in collaboration with Massachusetts General Hospital for the treatment of abdominal pain and visceral tenderness in patients suffering from irritable bowel syndrome. Each of the studies is utilising TRP-8802 (synthetic, oral psilocybin) to demonstrate clinical benefit in these indications. Where a positive clinical response is demonstrated, subsequent studies are expected to utilise TRP-8803 (IV-infused psilocin), that has the potential to further improve efficacy, safety, and patient experience.

For more information, please visit www.tryptherapeutics.com.

Investor & media enquiries:

Jason Carroll
Chief Executive Officer
Tryptamine Therapeutics Limited
jcarroll@tryptherapeutics.com

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

Risks associated with psilocin

All medicines carry risks and specialist prescribers, such as registered psychiatrists are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of psilocybin and similar compounds, such as psilocin, can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. These effects of psilocybin and its derivatives are unlikely at low doses and in the treatment regimens used in psychedelic-assisted psychotherapy and appropriately managed in a controlled environment with direct medical supervision.

Forward-Looking Information

Certain information in this news release, constitutes forward looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of Tryp's Replacement Prospectus available at www.asx.com.au These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

TRYPTAMINE THERAPEUTICS

Precision in Psychedelic Therapy



Biotech Showcase 2025, San Francisco, USA

ASX : TYP

This presentation has been authorised for release by the Board of Tryptamine Therapeutics Limited

Disclaimer

The information contained in this presentation (the "Presentation") has been prepared by Tryp Therapeutics Inc. ("Tryp" or the "Company") and contains information pertaining to the business, operations and assets of the Company. The information contained in this Presentation (a) is provided as at the date hereof and is subject to change without notice, (b) is for informational purposes only and does not purport to contain all information (including all material information) that may be necessary or desirable to fully and accurately evaluate the Company, (c) did not take into account the investment objectives, financial situation and particular needs of any particular investor, (d) is not to be considered as a recommendation by the Company that any person make an investment in Tryp, and (e) further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the Presentation. Those acting upon any information without advice do so entirely at their own risk.

This Presentation does not constitute an offer to sell or solicitation of an offer to buy any of the securities of Tryp. The sole purpose of this Presentation, in paper or electronic form, is strictly for information purposes. Neither Tryp, nor any of its current or proposed directors, officers, owners, managers, partners, consultants, employees, affiliates or representatives, make any warranty or representation, whether express or implied, or assume any legal liability or responsibility for any action taken in reliance upon this Presentation, or for the accuracy, completeness, fairness, or usefulness of any information disclosed in this Presentation.

Forward Looking Information. This Presentation contains forward looking statements with respect to Tryp. By their nature, forward looking statements involve risks and uncertainties and are subject to a variety of factors that could cause actual results to differ materially from the results suggested by the forward-looking statements. In addition, the forward-looking statements require Tryp to make assumptions and are subject to inherent risks and uncertainties. There is significant risk that the forward-looking statements will not prove to be accurate, that Tryp's assumptions may not be correct and that actual results may differ materially from such forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking statements. Generally, forward looking statements can be identified by the use of terminology such as "anticipate", "will", "expect", "may", "continue", "could", "estimate", "forecast", "plan", "potential" and similar expressions. Forward looking statements contained in this Presentation may include, but are not limited to statements with respect the outlook for the psilocybin industry and related industries; challenges and opportunities related to the psilocybin industry; the completion and timing of clinical studies; the ability of any patents resulting from Tryp's patent applications to protect the commercial prospects of its assets; the achievement, and the timing of, certain development milestones and the successful execution of Tryp's business strategy (including its business model and mission); the use and benefits of Tryp's products and services; demographic and market size/trends; forecasts of revenue and financial projections/growth potential; Tryp's ability to obtain marketing exclusivity for any of its approved drug products; anticipated capitalization, projected milestones and the go-forward management of Tryp; These forward looking statements are based on a number of assumptions which may prove to be incorrect including, but not limited to: general economic, market and business conditions, the outcome of research studies, the ability to obtain certain approvals, the accuracy of cost estimates, ability to obtain sufficient capital on satisfactory terms, availability of equipment and supplies, changes in customer demand, the successful and timely implementation of capital projects, currency exchange rates and the impact of changes in applicable laws and regulations. The forward-looking statements contained in this Presentation are made as of the date hereof or the dates specifically referenced in this Presentation, where applicable. Except as required by law, Tryp undertakes no obligation to update publicly or to revise any forward-looking statements that are contained or incorporated in this Presentation. All forward looking statements contained in this Presentation are expressly qualified by this cautionary statement.

Third-Party Information. This Presentation includes market and industry data obtained from various publicly available sources and other sources believed by the Company to be reliable. Although the Company believes it to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this Presentation or analyzed or verified the underlying reports relied upon or referred to by such sources, or ascertained the underlying assumptions relied upon by such sources. The Company does not make any representation or warranty, express or implied as to the accuracy of such information. .No responsibility or liability is accepted for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this Presentation. Some numbers in this Presentation may not be exact or add consistently due to rounding.

Accordingly, neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this Presentation or any document supplied with this Presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

Electronic Form. This Presentation may have been sent to you in an electronic form. You are reminded that documents transmitted via this medium may be altered or changed during the process of electronic transmission. You are responsible for protecting against viruses and other destructive items. Your receipt of this electronic transmission is at your own risk, and it is your responsibility to take precautions to ensure that it is free from viruses and other items of a destructive nature. As a consequence of the above, neither the Company nor any director, officer, employee or agent of any of them or any affiliate of any such person accepts any liability or responsibility whatsoever in respect of any difference between the document distributed to you in electronic format and the hard copy version that may be made available to you.

This Presentation and its contents are confidential and should not be distributed, published or reproduced in whole or in part or disclosed by recipients to any other person without the prior written consent of the Company. The Company does not assume responsibility for liabilities, losses or damages suffered by the recipients of this Presentation or any other person as a result of the circulation, reproduction or use of this Presentation.

Psilocybin. Psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (the "CDSA") and it is a criminal offence to possess substances under the CDSA without a prescription. Health Canada has not approved psilocybin as a drug. While the Company is focused on developing products using psilocybin, the Company does not have any direct or indirect involvement with the illegal selling, production or distribution of any substances. The Company does not currently manufacture, store or otherwise handle psilocybin directly and will only do so through agents within laboratory and clinical trial settings conducted within approved regulatory frameworks. The Company's products that contain psilocybin or other psychedelic compounds will not be commercialized prior to applicable regulatory approval, which will only be granted if clinical evidence of safety and efficacy for the intended uses is successfully developed.

All medicines carry risks and specialist prescribers, such as registered psychiatrists are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding.

Adverse effects of psilocybin and its derivatives can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. These effects of psilocybin and its derivatives are unlikely at low doses and in the treatment regimens used in psychedelic-assisted psychotherapy and appropriately managed in a controlled environment with direct medical supervision.

TRYPTAMINE THERAPEUTICS

Delivering Precision to Neuroplastic Medicine

With a focus on solving:

EATING DISORDERS & CHRONIC PAIN

Tryp is a clinical stage drug development company developing an innovative and scalable IV-infused psilocin solution which can be used with therapy to address unmet medical needs

Infusion refers to the continuous administration of the drug via the intravenous route and provides a clinician with full control over the administration of the solution

Corporate overview

Snapshot:	
ASX code:	TYP
Shares on issue:	1.227Bn
Market capitalisation: (at $0.04 per share)	AU$49.1m
Cash at bank: (as at 30 Sep 2024)	AU$5.3m*
Debt:	Nil

Board of Directors	
Non-Executive Chairman	Mr. Mark Davies
Chief Executive Officer	Mr. Jason Carroll
Non-Executive Director	Dr. Daniel Tillett
Non-Executive Director	Mr. Chris Ntoumenopoulos
Non-Executive Director	Mr. Gage Jull



Major shareholders (at 18 December 2024)	
Dr. William James Garner *(co-founder)*	15.5%
Citicorp Nominees P/L	7.5%
Mr. Jason Carroll *(CEO)*	2.9%
BNP Paribas Nominees P/L	2.7%
Mr. Herwig Janssen *(HNW/J&J Executive)*	2.0%
Top 5:	30.6%
Top 10:	38.7%
Top 20:	47.7%
Top 100:	80.5%

***Cash balance at 30 Sept 2024 excludes expected R&D Tax Rebate Incentive [AU$1.05M] and net capital from Tranche 2 raises [AU$3.05M]**

Investment highlights

Focused on the development of a best in class neuroplastegen and precise dosing in patients with neuropsychiatric disorders

A transformative and commercially scalable IP portfolio via the use of IV-infused psilocin (TRP-8803):

- TRP-8803 addresses the limitations of oral dosing – Include improvements in treatment time and the ability to reverse treatment quickly
- Platform has broad applicability and out-licensing potential across multiple indications

Strong clinical trial pipeline (completed and ongoing):

- Three pathfinder Phase 2 clinical trials - Binge Eating Disorder (complete), Fibromyalgia (complete) and Irritable Bowel Syndrome (ongoing)
- Each Phase 2 trial delivered meaningful results into specific indications using oral dosing (TRP-8802)
- Phase 1 healthy human volunteer study using TRP-8803 completed in 14 patients to define optimal infusion rates - TRP-8803 deemed safe by SRC
- Preparation for first active patient clinical study using TRP-8803 in Australia well advanced

A world-class team, partners and advisory board:

- Board and management include executives with over 20 years' experience in pharmacuteicala nd drug development
- Scientific Advisory Board lead by sector expert, Robin Carhart-Harris and underpinned by leading Australian professors
- Exceptional research partners including Massachusetts General Hospital, the University of Florida and others

Funded and well placed to capitalise on regulation:

- Australian listed entity allows company to benefit from positive regulatory stance and leverage government R&D incentives
- Recent A$6m placement with renowned biotechnology investors provides strong financial flexibility

Dispelling myths regarding pharmaceutical safety of Psilocybin



Efficacy in targeting serotonin $5\text{-}HT_{2A}$ receptors

TRYPTAMINE THERAPEUTICS



Psilocin molecules activate the serotonin $5HT_{2A}$ receptor due to structural similarity between psilocin & serotonin.



Psilocin occupancy of $5\text{-}HT_{2A}$ Receptors

Pharmaceutical potential for patients with neuropsychiatric conditions



Communication pathways after (a) placebo and (b) psilocybin.



The immense clinical potential of Psilocybin treatment

TRYPTAMINE THERAPEUTICS

Existing Clinical Programs include:

Treatment Resistant Depression [TRD]
Major Depressive Disorder [MDD]
Post-partum Depression
Post-Traumatic Stress Disorder [PTSD]
Obsessive Compulsive Disorder [OCD]
Depression in Bipolar-2 Disorder
Generalized Anxiety Disorder [GAD]
Body Dysmorphic Disorder [BDD]
Anorexia Nervosa
Binge Eating Disorder [BED]
Fibromyalgia Syndrome [FMS]
Irritable Bowel Syndrome [IBS]

Phantom Limb Pain
Migraine
Cluster Headache
Concussion Headache
Methamphetamine Use Disorder
Cocaine Use Disorder
Alcohol Use Disorder
Gambling Addiction
Smoking Cessation/Nicotine Addiction
Demoralization
Cancer-related mood & anxiety disorders

But how can the the clear clinical potential of Psilocybin be harnessed?

IV-infused Psilocin: A Precision Approach in Neuropsychiatry

	IV-infused Psilocin	Oral Psilocybin *
Short treatment duration of 1-2 hours	✓	✗ ~8-10 hours
Quick onset of psychedelic state (~15 minutes)	✓	✗ 1-2 hours
Precision targeting of drug blood levels in patients	✓	✗ highly variable
Quickly reversible in emergency	✓	✗
Strong IP positioning	✓	✗
Commercially scalable	✓	?

* Companies developing oral psilocybin include: Compass Pathways, USONA

Interpatient variability of oral psilocybin 25mg



Volume 113, Issue
April 2023
Pages 747-751

Adapted from : Clin Pharma and Therapeutics, Volume: 113, Issue: 4, Pages: 822-831, First published: 12 December 2022, DOI: (10.1002/cpt.2821)

Comparison of Psilocin Blood Level Variability:
Oral Psilocybin vs TRP-8803 IV Infusion

Oral Psilocybin



TRP-8803



Clinical Trial Pipeline



*Healthy volunteer dose ranging study in 2024 will support IND submissions for Phase 2a studies in patients
**The timetable is indicative only and is subject to change.

Binge Eating Disorder (BED) : TRP 8802: Phase 2a clinical trial

Recurring episodes of eating large quantities of food and feeling unable to stop

25-50% of obese patients who seek weight-loss treatment suffer from problems with Binge Eating[1]

No currently approved treatments developed specifically for Binge Eating Disorder

Patients suffering from BED have multiple co-morbidities[2]:
- 94% have lifetime Psychiatric disorders
- 70% Mood disorders
- 59% Depression
- 32% PTSD
- 23% of BED sufferers have attempted suicide

"We are very excited for the potential of TRYP's treatment. The potential impact on patients' lives is that it would be life changing for them."

Jennifer Miller, MD, Professor, University of Florida, Principal Investigator

"These results from a single dose of psilocybin combined with therapy are clinically meaningful and highly promising. The magnitude of changes for most participants in binge eating, anxiety, and depression are dramatic.."

Jessie Dallery, Ph.D. Professor, University of Florida, Lead Psychologist

PRODUCT	NO. OF PATIENTS	COLLABORATOR	DESIGN	DATA READ OUT	NEXT STEPS
TRP-8802	6	UF UNIVERSITY of FLORIDA	Open label with psychotherapy	Data announced Q1 2023	Scientific paper publication

Positive interim data announced in January 2023, including mean reduction >80% for Binge Eating Score confirmed as viable target for future studies using TRP-8803

1. *Bruce et.al.; Journal of the ADA,* Volume 96, Issue 1, Jan 1996, PP 58-61, *Binge Eating Among the Overweight Population: A Serious and Prevalent Problem*
2. *Keski-Rahkonen: Current Opinion in Psychiatry* 34(6):p 525-531, November 2021. *Epidemiology of Binge Eating Disorder: prevalence, course, comorbidity & risk factors*

University of Florida Phase 2a BED Study Analysis:

Significant reduction in frequency & extent of binge eating (daily, 4 weeks)





University of Florida Phase 2a Study Analysis:

Significant fall in Hospital Anxiety & Depression Scores (HADS)



HADS Anxiety Score



HADS Depression Score

University of Florida Phase 2a Study Analysis:

Durable effect on binge eating episodes



Fibromyalgia: TRP 8802: Phase 2a clinical trial

FMS characterized by widespread musculoskeletal pain, profound fatigue, sleep disturbances, and numerous other symptoms[1]

Symptoms of fibromyalgia often begin after physical or emotional trauma, such as an illness, surgery, infection, life event or injury[2]

While fibromyalgia pain feels like it's coming from a specific area of your body, it's actually originating in your brain, specifically from the nervous system[2]

Many drugs have a limited effect on Fibromyalgia Pain[1]

Co-morbidities include depression and health-related anxiety, sleep disturbances and increased suicide risk[2]



Marks, J.; What is Fibromyalgia?

PRODUCT	NO. OF PATIENTS	COLLABORATOR	DESIGN	DATA READ OUT	NEXT STEPS
TRP-8802	Up to 10	UNIVERSITY OF MICHIGAN	Open label with psychotherapy	Initial Data Available	Full Clinical Study Data Release & 3 month follow up

First patient dosed in December 2023 with Data presented August 2024

1. *Giorgi et.al.; Current Pain & Headache Reports; 23 July 2024; Pharmacological Treatment of Fibromyalgia Syndrome: A Practice-Based Review*
2. *Marks, J.; What is Fibromyalgia? Symptoms, Causes, Diagnosis, Treatment & Prevention; Everydayhealth.com/fibromyalgia/guide; Dec 15 2022*

Change in Fibromyalgia symptoms following TRP-8802 administration:

(Baseline vs. end of treatment) for n=5 participants



For T-scores, **changes of 2-6 points are considered a meaningful change**. For **pain severity, a 2-point difference is considered clinically significant**.
https://www.healthmeasures.net/score-and-interpret/interpret-scores/promis/meaningful-change

*Indicates secondary Outcome. CPAQ: Chronic Pain Acceptance Questionnaire. Pain Severity reported as change in aggregate pain score from the 7 days prior to the intervention to the end of the intervention. Sleep disturbance, pain interference, physical function, anxiety, depression, fatigue, participation in social activities, and cognitive abilities are all reported as T-scores per PROMIS scoring. Negative change scores indicate improvement for pain severity, pain interference, sleep disturbance, FM score, anxiety, depression, and fatigue. Positive change scores indicate improvement for CPAQ, physical function, participation in social activities, and cognitive abilities.

Irritable Bowel Syndrome (IBS) : TRP-8802 : Phase 2a clinical trial

TRYPTAMINE THERAPEUTICS

Chronic abdominal pain + altered bowel habits

Affects 10-15% worldwide (~790M people)[1]; leading cause of work absenteeism[2]

Associated with fibromyalgia, chronic fatigue, depression & anxiety

More common in those with early life adversity/trauma

Pathophysiology: visceral hypersensitivity

90% of serotonin synthesized in gut; enteric nervous system[3]

"There is tremendous potential for the treatment of debilitating IBS and other disorders of gut-brain interaction by utilizing the combined administration of psilocybin and psychotherapy. Our clinical study will examine how psilocybin-assisted psychotherapy may alter important brain networks involved in chronic pain and gastrointestinal-specific anxiety in IBS to bolster the neural flexibility in these patients and thereby reduce visceral hypersensitivity"

Erin Mauney, MD, Massachusetts General Hospital

PRODUCT	NO. OF PATIENTS	COLLABORATOR	DESIGN	DATA READ OUT	NEXT STEPS
TRP-8802	Up to 10	MASSACHUSETTS GENERAL HOSPITAL	Open label with psychotherapy	H2 2024	Dose completion

Four patients dosed July – Sept 2024; Next steps Dosing Completion

1. https://gi.org/topics/irritable-bowel-syndrome
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010380/
3. https://www.nature.com/articles/s41598-022-05756-0

Patient 1 pain diary:



*Patient 1 diary-reported scoring of abdominal pain severity (out of 10) from Phase 2a Interim Analysis – MGH

TRP-8803: Healthy Human Volunteer Study (Australia):

A global first study now complete

IV-Infused Psilocin

- Precision targeting of psilocin blood levels
- Fast onset time to psychedelic state (less than 20 mins)
- Short duration of treatment compared with oral psilocybin
- No weight-based dosing required
- Fully reversible in emergency
- IP protection
- Commercially scalable
- Enables clinical studies in multiple indications
- Safety Review Council finds TRP-8803 safe & well tolerated

HREC approved trial completed August 2024

PRODUCT	NO. OF PATIENTS	COLLABORATOR	DESIGN	DATA READ OUT	NEXT STEPS
TRP-8803	14 incl. 3 obese	iNGENu, C-Max	Open label with therapist support	H2 2024	Safety Review Council Report

Preliminary Results Phase I TRP-8803 Clinical Safety & Dose Ranging Study

TRP-8803 Achieves Consistent Blood Levels between Cohorts



- Established Safety of TRP-8803
- Confirmed Ability to achieve target blood levels of psilocin
- Confirmed reversibility of TRP-8803
- Achieved desired PK profile to reduce Side Effects while
- Established doses and infusion rates to be tested in Phase 2 Patient Studies

Robust Intellectual Property Portfolio

Patent applications and trade secrets based on novel methods for manufacturing, formulation, dosing, and specific disease indications

- Filed a provisional patent in March 2021 (US 63/161,070) covering TRP-8803 (**IV-infused Psilocin**); converted to PCT filing March 2022; published September 22, 2022
- Provisional patent application covering the use of psilocybin in the treatment of Binge Eating Disorder (BED) filed June 2022
- Provisional patent application for the treatment of fibromyalgia submitted September 2022
- Provisional patent application for salt & co-formers of TRP-8803 filed September 2022
- Provisional patent for IBS filed January 2, 2023

MORRISON FOERSTER

Allens › ‹ Linklaters

Multiple Near-Term Milestones and Catalysts*

TRYPTAMINE THERAPEUTICS

Catalyst	Timeframe	Status
Completion of Tryp Therapeutics Inc. acquisition	H1 2024	✔
$6.5m capital raise	H1 2024	✔
Recommencement of trading on ASX	H1 2024	✔
Appointments to strengthen Scientific Advisory Board	H1 2024	✔
Start of TRP-8803 Phase 1 trial (Australia)	H1 2024	✔
TRP-8802 Fibromyalgia Phase 2a patient enrolment (in collaboration with University of Michigan)	H1 2024	✔
TRP-8802 Irritable Bowel Syndrome (IBS) Phase 2a trial commencement (alongside Harvard University)	H2 2024	✔
Completion of TRP-8803 Phase 1 trial (Australia) and interim results	H2 2024	✔
TRP-8802 Fibromyalgia Phase 2a interim data	H1 2025	✔
TRP-8802 IBS Phase 2a interim data	*H2 2024* ~~*H1 2025*~~	✔
TRP-8802 Fibromyalgia Phase 2a final data	H1 2025	
TRP-8803 Phase 2 trial authorisations	H1 2025	
TRP-8803 Phase 2 trial eating disorder trial commencement (Australia)	H1 2025	
TRP-8802 IBS Phase 2a final data	*H1 2025* ~~*H2 2025*~~	
Commencement of TRP-8803 Phase 2 Binge Eating Disorder [BED] Trial (Australia)	H1 2025	
Commencement of TRP-8803 Phase 2 Fibromyalgia (chronic) pain Trial (Australia)	H2 2025	

*The timetable is indicative only and is subject to change (Calendar year is used)

TRYPTAMINE THERAPEUTICS

Contact

Jason Carroll
Chief Executive Officer
jcarroll@tryptherapeutics.com

Henry Jordan
Six Degrees Investor Relations
henry.jordan@sdir.com.au

Website:
www.tryptherapeutics.com

Socials:
X (Twitter) @tryptherapeutic